BridgeBio Oncology Therapeutics, Inc.

$4.66Close · Sep 22, 2026

News

BBO-11818: an orally bioavailable, highly potent and selective non-covalent pan-KRAS(ON) and (OFF) inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models
Apr 21, 2026BridgeBio Oncology Therapeutics
APRIL 2026 • AACR 2026 The post BBO-11818: an orally bioavailable, highly potent and selective non-covalent pan-KRAS(ON) and (OFF) inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models first appeared on BridgeBio Oncology Therapeutics.
The RAS:PI3Kα Breaker BBO-10203 inhibits PI3Kα/AKT activity in HER2AMP models through non-canonical RAS signaling blockade
Apr 21, 2026BridgeBio Oncology Therapeutics
APRIL 2026 • AACR 2026 The post The RAS:PI3Kα Breaker BBO-10203 inhibits PI3Kα/AKT activity in HER2AMP models through non-canonical RAS signaling blockade first appeared on BridgeBio Oncology Therapeutics.
BBO-11818, an orally bioavailable, highly potent and non-covalent pan-KRAS inhibitor demonstrates robust anti-tumor activity in KRAS-mutant preclinical models
May 16, 2025BridgeBio Oncology Therapeutics
April 2025 • AACR 2025 The post BBO-11818, an orally bioavailable, highly potent and non-covalent pan-KRAS inhibitor demonstrates robust anti-tumor activity in KRAS-mutant preclinical models first appeared on BridgeBio Oncology Therapeutics.
BBO-8520, a first-in-class direct dual inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRASG12C, exhibits robust efficacy in non-small cell lung cancer preclinical models
May 16, 2025BridgeBio Oncology Therapeutics
April 2025 • AACR 2025 The post BBO-8520, a first-in-class direct dual inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRASG12C, exhibits robust efficacy in non-small cell lung cancer preclinical models first appeared on BridgeBio Oncology Therapeutics.
BBOT Announces First Patient Dosed with BBO-11818, a PanKRAS Dual Inhibitor, in the Phase 1 KONQUER-101 Trial for Advanced Solid Tumors
Apr 1, 2025BridgeBio Oncology Therapeutics
April 1, 2025 The post BBOT Announces First Patient Dosed with BBO-11818, a PanKRAS Dual Inhibitor, in the Phase 1 KONQUER-101 Trial for Advanced Solid Tumors first appeared on BridgeBio Oncology Therapeutics.
Beyond First-Generation KRAS Inhibitors: BBO-8520 Tests the Dual Mechanism Hypothesis
Mar 11, 2025BridgeBio Oncology Therapeutics
March 2025 • AACR Cancer Discovery The post Beyond First-Generation KRAS Inhibitors: BBO-8520 Tests the Dual Mechanism Hypothesis first appeared on BridgeBio Oncology Therapeutics.
BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines
Feb 28, 2025BridgeBio Oncology Therapeutics
February 28, 2025 The post BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines first appeared on BridgeBio Oncology Therapeutics.
BridgeBio Oncology Therapeutics (BBOT) Granted U.S. FDA Fast Track Designation for BBO-8520 for KRASG12C-Mutated Metastatic Non-Small Cell Lung Cancer
Jan 9, 2025BridgeBio Oncology Therapeutics
January 9, 2025 The post BridgeBio Oncology Therapeutics (BBOT) Granted U.S. FDA Fast Track Designation for BBO-8520 for KRASG12C-Mutated Metastatic Non-Small Cell Lung Cancer first appeared on BridgeBio Oncology Therapeutics.
BridgeBio Oncology Therapeutics (BBOT) to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025
Dec 23, 2024BridgeBio Oncology Therapeutics
December 23, 2024 The post BridgeBio Oncology Therapeutics (BBOT) to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025 first appeared on BridgeBio Oncology Therapeutics.
BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
May 2, 2024BridgeBio Oncology Therapeutics
May 2, 2024 The post BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline first appeared on BridgeBio Oncology Therapeutics.